BidaskClub upgraded shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a hold rating to a buy rating in a research report released on Friday morning, BidAskClub reports.

A number of other analysts have also recently commented on the company. HC Wainwright reaffirmed a buy rating and issued a $32.00 price target (up from $29.00) on shares of Karyopharm Therapeutics in a research note on Friday, July 5th. Robert W. Baird reaffirmed an outperform rating and issued a $25.00 price target (up from $15.00) on shares of Karyopharm Therapeutics in a research note on Friday, July 5th. ValuEngine raised Karyopharm Therapeutics from a buy rating to a strong-buy rating in a research note on Thursday, September 5th. Zacks Investment Research cut Karyopharm Therapeutics from a buy rating to a hold rating in a research note on Saturday, July 13th. Finally, Wedbush upped their price target on Karyopharm Therapeutics from $6.00 to $11.00 in a research note on Monday, July 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $17.32.

Shares of KPTI stock opened at $11.85 on Friday. The company has a debt-to-equity ratio of 1.46, a current ratio of 6.93 and a quick ratio of 6.93. The stock has a market cap of $724.46 million, a PE ratio of -3.77 and a beta of 2.41. The stock has a 50-day moving average of $9.08 and a 200-day moving average of $6.58. Karyopharm Therapeutics has a one year low of $3.92 and a one year high of $19.19.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.26. The company had revenue of $9.49 million during the quarter. Karyopharm Therapeutics had a negative return on equity of 154.75% and a negative net margin of 2,138.80%. As a group, research analysts anticipate that Karyopharm Therapeutics will post -3.64 earnings per share for the current year.

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of Montreal Can acquired a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at approximately $29,000. BNP Paribas Arbitrage SA grew its position in shares of Karyopharm Therapeutics by 169,300.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 10,164 shares of the company’s stock valued at $59,000 after purchasing an additional 10,158 shares during the period. Envestnet Asset Management Inc. grew its position in shares of Karyopharm Therapeutics by 12.4% in the 2nd quarter. Envestnet Asset Management Inc. now owns 11,980 shares of the company’s stock valued at $72,000 after purchasing an additional 1,319 shares during the period. Parametric Portfolio Associates LLC acquired a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at approximately $128,000. Finally, Premier Asset Management LLC acquired a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at approximately $160,000. Institutional investors and hedge funds own 82.55% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for
the treatment of cancer and other major diseases. Karyopharm’s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).

Further Reading: Mutual Funds

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.